On March 28, 2019, Chen, Chen published a patent.Computed Properties of 175357-98-9 The title of the patent was Preparation of cyclic iminopyrimidine derivatives as B-Raf V600E kinase inhibitors. And the patent contained the following:
The invention relates to cyclic iminopyrimidine compounds and their bicyclic derivatives of formula I and their preparation, useful in treating proliferation disorders such as cancer or tumors or for diseases or disorders related to the dysregulation of kinase such as, but not limited to B-Raf V600E kinase. Compounds of formula I are claimed, in which X1, X2, X3, Y1, Y2, and Y3 are each independently N and (un)substituted CH; Z1 is O, S, and (un)substituted NH and CH2; Z2 is bond and NH and derivatives; m = 0-3, n = 1-3; R1-R3 are each independently H, halo, CN, NO2, (un)substituted C1-6 alkyl, etc.; R4 is H and C1-6 alkyl; or pharmaceutically acceptable salts, solvates, or isotopic derivatives thereof. Example compound II was prepared via a multistep process (procedure given). Invention compounds were evaluated for their B-Raf V600E kinase inhibitory activity. From the assay, it was determined that II exhibited growth inhibition of 50% (GI50) at <100 nM. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Computed Properties of 175357-98-9
The Article related to cyclic iminopyrimidine dihydroimidazoquinazoline preparation kinase inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 175357-98-9
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia